Abstract
898 Background: Letrozole reduces breast cancer recurrences in postmenopausal women following completion of 5 years of tamoxifen. Providing informed decision-making for the large number of women eligible, now and in the future, creates a considerable burden on oncology physician resources. This may result in delays in information dissemination and treatment. Objectives of this study are to develop a self-administered decision-making guide for women eligible to take letrozole post tamoxifen and to determine the effect of this guide when included with a letter of invitation to discuss letrozole therapy. Methods: Women currently over 50 years of age, who had stage I-III, ER/PR positive or unknown breast cancer diagnosed between 1997 and 1999 and without recurrences, were identified from the Manitoba Cancer Registry. All women received a letter of invitation to make an appointment with an oncologist to discuss letrozole. They were randomized to receive a decision-making guide either with the letter (G1) or ju...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
